Zimmer, Biomet complete $13.35 billion merger
The Indiana-based company has taken the name Zimmer Biomet Holdings Inc. and will trade under the ticker symbol to "ZBH" on Monday. Zimmer Holdings Inc. agreed to buy privately-held Biomet in April 2014.
The Indiana-based company has taken the name Zimmer Biomet Holdings Inc. and will trade under the ticker symbol to "ZBH" on Monday. Zimmer Holdings Inc. agreed to buy privately-held Biomet in April 2014.
About 160,000 low- and moderate-income Indiana residents could lose health insurance premium subsidies provided under the Affordable Care Act if the U.S. Supreme Court rules them illegal, two groups estimated Tuesday.
In a new scoring system for oncology drugs, a leading group of U.S. cancer doctors awarded a zero for overall benefit to a regimen featuring Alimta, Eli Lilly and Co.’s top-selling product.
After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
Kem Hawkins, who has been president of Cook Group Inc. since 2001, will retire on July 1. He will be replaced by Pete Yonkman, who since 2013 has been president of Cook Medical, the Cook subsidiary that makes medical devices.
The acquisition lets Hill-Rom, a maker of hospital supplies for wound care and respiratory health, delve further into the market for diagnostic supplies for physicians and emergency responders
The biggest U.S. providers—UnitedHealth Group Inc., Anthem Inc., Aetna Inc., Cigna Corp. and Humana Inc.—are all looking at possible combinations. Indianapolis-based Anthem is considering a takeover of Cigna or Humana, a person familiar with the matter said.
Anthem Inc. has made a buyout offer to rival health insurer Cigna Corp. for $45 billion, The Wall Street Journal reported Monday. That price would make the deal the largest health insurance merger in U.S. history.
Intarcia Therapeutics Inc. is betting its matchstick-size pump could take market share from Eli Lilly and Co., AstraZeneca Plc and Novo Nordisk A/S.
Target Corp. has agreed to sell its pharmacy and clinic businesses to the drugstore chain CVS Health Corp. for about $1.9 billion in a deal that combines the resources of two retailers seeking to polish their health care reputations.
Axovant Sciences Ltd., a company without a finished product or a dime of sales, has an almost $3 billion valuation after its public-market debut. The IPO shows the staggering potential for any company that can develop a successful Alzheimer’s treatment.
Anthem Blue Cross and Blue Shield has added St. Vincent Health to the “narrow network” of health care providers it uses for Obamacare plans.
The National Labor Relations Board declined to dismiss charges that IU Health broke the law by firing one nurse and disciplining another who were involved in trying to form a union at Methodist Hospital.
Dr. Kent Brantly was awarded the Dr. Nathan Davis International Award in Medicine from the American Medical Association for his service in Liberia during last summer’s Ebola outbreak.
Progress in reducing smoking is undeniable, but money to accelerate the decline is falling even faster.
Millions of people will be able to see a doctor on their smartphones or laptops for everyday ailments once the nation's largest drugstore chain and two major insurers expand a budding push into virtual health care.
A medical software company is notifying patients of the health care providers it serves—including Franciscan St. Francis Health in Indianapolis—that their private information may have been exposed when its networks were hacked.
Eli Lilly stock rose 5.4 percent per share on Tuesday, its biggest daily increase since March 2009, after Elanco President Jeffrey Simmons was asked if Lilly might one day shed the unit in an initial public offering.
Indianapolis-based Eli Lilly and Co. plans to introduce its version of Sanofi’s Lantus insulin for diabetes in Europe in the third quarter, said Enrique Conterno, the president of Lilly Diabetes.
An experimental pill to treat low sexual desire in women moved closer to becoming the first such drug to be sold in the U.S. after regulatory advisers backed its approval.